Two Sigma Advisers
XENE icon

Two Sigma Advisers’s Xenon Pharmaceuticals XENE Stock Holding History

Two Sigma Advisers’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-259,320
Closed -$11.6M – 2186
2025
Q4 		$11.6M Buy
259,320
+241,220
+1,333% +$10.1M 0.02% 492
2025
Q3 		$727K Sell
18,100
-77,200
-81% -$2.72M ﹤0.01% 1610
2025
Q2 		$2.98M Sell
95,300
-203,500
-68% -$6.64M 0.01% 945
2025
Q1 		$10M Buy
298,800
+100
+0% +$3.8K 0.02% 530
2024
Q4 		$11.7M Buy
298,700
+25,000
+9% +$1.03M 0.03% 441
2024
Q3 		$10.8M Buy
273,700
+64,800
+31% +$2.61M 0.03% 470
2024
Q2 		$8.15M Sell
208,900
-20,300
-9% -$811K 0.02% 597
2024
Q1 		$9.87M Sell
229,200
-23,500
-9% -$1.08M 0.02% 542
2023
Q4 		$11.6M Buy
252,700
+187,800
+289% +$6.64M 0.03% 471
2023
Q3 		$2.22M Buy
+64,900
New +$2.43M 0.01% 1131
2023
Q1 		– Sell
-22,700
Closed -$895K – 2773
2022
Q4 		$895K Sell
22,700
-68,300
-75% -$2.49M ﹤0.01% 1622
2022
Q3 		$3.29M Buy
91,000
+38,700
+74% +$1.39M 0.01% 939
2022
Q2 		$1.59M Sell
52,300
-70,400
-57% -$2.13M ﹤0.01% 1328
2022
Q1 		$3.75M Sell
122,700
-3,900
-3% -$117K 0.01% 930
2021
Q4 		$3.96M Sell
126,600
-49,200
-28% -$1.47M 0.01% 875
2021
Q3 		$2.69M Buy
175,800
+92,800
+112% +$1.61M 0.01% 1090
2021
Q2 		$1.54M Sell
83,000
-5,900
-7% -$109K ﹤0.01% 1431
2021
Q1 		$1.59M Sell
88,900
-9,600
-10% -$163K ﹤0.01% 1387
2020
Q4 		$1.51M Sell
98,500
-7,200
-7% -$84.2K ﹤0.01% 1393
2020
Q3 		$1.17M Buy
105,700
+4,800
+5% +$56.5K ﹤0.01% 1434
2020
Q2 		$1.26M Buy
100,900
+37,400
+59% +$476K ﹤0.01% 1458
2020
Q1 		$720K Buy
63,500
+30,400
+92% +$433K ﹤0.01% 1641
2019
Q4 		$434K Buy
33,100
+6,200
+23% +$65.2K ﹤0.01% 1926
2019
Q3 		$242K Sell
26,900
-5,700
-17% -$53.9K ﹤0.01% 1992
2019
Q2 		$321K Sell
32,600
-4,500
-12% -$43.1K ﹤0.01% 1991
2019
Q1 		$377K Buy
37,100
+900
+2% +$7.63K ﹤0.01% 1905
2018
Q4 		$228K Buy
+36,200
New +$322K ﹤0.01% 2090

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Two Sigma Advisers's XENE Position: Q1 2026 in Review

Two Sigma Advisers sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 259,320 shares — an estimated $11.6M sold.

Two Sigma Advisers first reported a position in XENE in Q4 2018 and held it in 27 quarters. The position peaked at $11.7M in Q4 2024. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Two Sigma Advisers reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 259,320 Xenon Pharmaceuticals shares in Q1 2026, an estimated $11.6M.
  • Two Sigma Advisers first reported a position in Xenon Pharmaceuticals in Q4 2018 and held it in 27 quarters.
  • Two Sigma Advisers's Xenon Pharmaceuticals position peaked at $11.7M in Q4 2024.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.